CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade AVITA Medical, Inc. - RCEL CFD

    9.66
    2.33%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    AVITA Medical Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 9.44
    Open* 9.48
    1-Year Change* -39.46%
    Day's Range* 9.41 - 10.02
    52 wk Range 8.06-21.70
    Average Volume (10 days) 129.44K
    Average Volume (3 months) 3.20M
    Market Cap 355.41M
    P/E Ratio -100.00K
    Shares Outstanding 25.55M
    Revenue 45.40M
    EPS -1.33
    Dividend (Yield %) N/A
    Beta 1.38
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 15, 2024 9.44 -0.42 -4.26% 9.86 9.88 9.27
    Apr 12, 2024 9.83 -0.40 -3.91% 10.23 10.54 9.64
    Apr 11, 2024 10.32 -1.90 -15.55% 12.22 12.25 9.83
    Apr 10, 2024 14.38 0.01 0.07% 14.37 14.62 14.09
    Apr 9, 2024 14.94 -0.13 -0.86% 15.07 15.20 14.64
    Apr 8, 2024 15.10 -0.18 -1.18% 15.28 15.41 14.94
    Apr 5, 2024 15.32 0.35 2.34% 14.97 15.55 14.97
    Apr 4, 2024 15.05 -0.02 -0.13% 15.07 15.60 14.99
    Apr 3, 2024 15.09 0.12 0.80% 14.97 15.31 14.85
    Apr 2, 2024 15.19 -0.03 -0.20% 15.22 15.60 15.12
    Apr 1, 2024 15.52 -0.31 -1.96% 15.83 15.92 15.16
    Mar 28, 2024 15.94 0.15 0.95% 15.79 16.55 15.79
    Mar 27, 2024 16.43 0.42 2.62% 16.01 16.44 15.74
    Mar 26, 2024 15.93 0.16 1.01% 15.77 16.16 15.77
    Mar 25, 2024 15.81 0.30 1.93% 15.51 16.08 15.51
    Mar 22, 2024 15.65 0.08 0.51% 15.57 15.91 15.52
    Mar 21, 2024 16.10 -0.02 -0.12% 16.12 16.52 16.06
    Mar 20, 2024 16.12 0.34 2.15% 15.78 16.35 15.36
    Mar 19, 2024 15.98 0.40 2.57% 15.58 16.23 15.48
    Mar 18, 2024 15.80 -0.67 -4.07% 16.47 16.65 15.53

    AVITA Medical, Inc. Events

    Time (UTC) Country Event
    Thursday, May 9, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q1 2024 AVITA Medical Inc Earnings Release
    Q1 2024 AVITA Medical Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, May 13, 2024

    Time (UTC)

    20:30

    Country

    US

    Event

    Q1 2024 AVITA Medical Inc Earnings Call
    Q1 2024 AVITA Medical Inc Earnings Call

    Forecast

    -

    Previous

    -
    Wednesday, June 5, 2024

    Time (UTC)

    22:00

    Country

    US

    Event

    AVITA Medical Inc Annual Shareholders Meeting
    AVITA Medical Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -

    Time (UTC)

    22:00

    Country

    US

    Event

    AVITA Medical Inc Annual Shareholders Meeting
    AVITA Medical Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2021 2020
    Total revenue 34.421 13.956 29.232 14.263
    Revenue 34.421 13.956 29.232 14.263
    Cost of Revenue, Total 5.666 1.861 5.723 2.667
    Gross Profit 28.755 12.095 23.509 11.596
    Total Operating Expense 61.926 28.379 55.772 56.942
    Selling/General/Admin. Expenses, Total 45.243 19.426 37.06 49.434
    Research & Development 13.857 7.586 14.818 8.461
    Unusual Expense (Income) 0.375 0.086 0.226 0.306
    Other Operating Expenses, Total -3.215 -0.58 -2.055 -3.926
    Operating Income -27.505 -14.423 -26.54 -42.679
    Interest Income (Expense), Net Non-Operating -0.016 -0.017 -0.022 -0.033
    Other, Net 0.892 0.038 0.017 0.686
    Net Income Before Taxes -26.629 -14.402 -26.545 -42.026
    Net Income After Taxes -26.665 -14.427 -26.583 -42.03
    Net Income Before Extra. Items -26.665 -14.427 -26.583 -42.03
    Net Income -26.665 -14.427 -26.583 -42.03
    Income Available to Common Excl. Extra. Items -26.665 -14.427 -26.583 -42.03
    Income Available to Common Incl. Extra. Items -26.665 -14.427 -26.583 -42.03
    Diluted Net Income -26.665 -14.427 -26.583 -42.03
    Diluted Weighted Average Shares 25.0002 24.9154 22.6743 20.291
    Diluted EPS Excluding Extraordinary Items -1.06659 -0.57904 -1.17238 -2.07137
    Diluted Normalized EPS -1.05684 -0.5768 -1.16591 -2.06156
    Dividends per Share - Common Stock Primary Issue 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 11.753 10.55 9.455 9.092 8.335
    Revenue 11.753 10.55 9.455 9.092 8.335
    Cost of Revenue, Total 2.202 1.6 1.256 1.405 1.325
    Gross Profit 9.551 8.95 8.199 7.687 7.01
    Total Operating Expense 22.918 20.461 15.363 14.84 14.697
    Selling/General/Admin. Expenses, Total 16.162 14.815 11.663 10.333 10.763
    Research & Development 5.076 4.586 3.379 3.799 3.059
    Unusual Expense (Income) 0.002 0.067 0.091 0.125 0.061
    Other Operating Expenses, Total -0.53 -0.627 -1.026 -0.904 -0.551
    Operating Income -11.165 -9.911 -5.908 -5.748 -6.362
    Interest Income (Expense), Net Non-Operating -0.007 -0.004 -0.006 -0.006 -0.004
    Other, Net 0.801 0.725 0.585 0.17 0.109
    Net Income Before Taxes -10.371 -9.19 -5.329 -5.584 -6.257
    Net Income After Taxes -10.384 -9.22 -5.353 -5.588 -6.261
    Net Income Before Extra. Items -10.384 -9.22 -5.353 -5.588 -6.261
    Net Income -10.384 -9.22 -5.353 -5.588 -6.261
    Income Available to Common Excl. Extra. Items -10.384 -9.22 -5.353 -5.588 -6.261
    Income Available to Common Incl. Extra. Items -10.384 -9.22 -5.353 -5.588 -6.261
    Diluted Net Income -10.384 -9.22 -5.353 -5.588 -6.261
    Diluted Weighted Average Shares 25.2397 25.2021 25.0837 25.007 24.9712
    Diluted EPS Excluding Extraordinary Items -0.41141 -0.36584 -0.21341 -0.22346 -0.25073
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.41136 -0.36411 -0.21105 -0.22021 -0.24914
    Interest Expense (Income) - Net Operating 0.006 0.02 0.082 0.04
    • Annual
    • Quarterly
    2022 2021 2021 2020
    Total Current Assets 87.458 92.132 121.33 78.387
    Cash and Short Term Investments 79.342 85.16 110.746 73.639
    Cash 73.639
    Total Receivables, Net 4.96 3.513 7.883 2.507
    Accounts Receivable - Trade, Net 3.935 3.19 3.467 2.076
    Total Inventory 2.125 2.132 1.647 1.125
    Prepaid Expenses 0.921 1.124 0.853 0.792
    Other Current Assets, Total 0.11 0.203 0.201 0.324
    Total Assets 98.264 116.015 125.501 82.462
    Property/Plant/Equipment, Total - Net 2.051 2.806 2.938 3.71
    Property/Plant/Equipment, Total - Gross 4.203 4.501 4.359 4.591
    Accumulated Depreciation, Total -2.152 -1.695 -1.421 -0.881
    Intangibles, Net 0.465 0.443 0.472 0.364
    Other Long Term Assets, Total 1.36 0.942 0.761 0.001
    Total Current Liabilities 10.693 9.146 7.39 7.709
    Payable/Accrued 3.002 2.708 3.12 4.333
    Accrued Expenses 7.235 6.083 4.023 3.349
    Notes Payable/Short Term Debt 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.011
    Other Current Liabilities, Total 0.456 0.355 0.247 0.016
    Total Liabilities 13.524 11.391 9.846 10.061
    Total Long Term Debt 0 0 0 0
    Other Liabilities, Total 2.831 2.245 2.456 2.352
    Total Equity 84.74 104.624 115.655 72.401
    Common Stock 0.003 0.003 0.003 0.003
    Additional Paid-In Capital 339.825 332.484 328.889 259.165
    Retained Earnings (Accumulated Deficit) -262.588 -235.923 -221.496 -194.913
    Other Equity, Total 7.5 8.06 8.259 8.146
    Total Liabilities & Shareholders’ Equity 98.264 116.015 125.501 82.462
    Total Common Shares Outstanding 25.2084 24.9257 24.8959 21.4679
    Cash & Equivalents 18.164 55.511 110.746
    Short Term Investments 61.178 29.649
    Long Term Investments 6.93 19.692
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 73.927 77.495 82.761 87.458 91.72
    Cash and Short Term Investments 60.118 66.047 73.451 79.342 84.172
    Cash
    Total Receivables, Net 7.886 7.015 5.37 4.96 4.508
    Accounts Receivable - Trade, Net 6.159 6.048 4.825 3.935 3.699
    Total Inventory 4.377 3.058 2.811 2.125 1.96
    Prepaid Expenses 1.509 1.375 1.116 0.921 0.862
    Other Current Assets, Total 0.037 0 0.013 0.11 0.218
    Total Assets 81.014 86.33 92.622 98.264 99.932
    Property/Plant/Equipment, Total - Net 4.469 3.249 3.148 2.051 2.255
    Property/Plant/Equipment, Total - Gross 6.726 5.64 5.426 4.203 4.284
    Accumulated Depreciation, Total -2.257 -2.391 -2.278 -2.152 -2.029
    Intangibles, Net 0.459 0.456 0.461 0.465 0.449
    Other Long Term Assets, Total 2.159 2.376 2.063 1.36 1.496
    Total Current Liabilities 11.836 13.81 11.486 10.693 9.513
    Payable/Accrued 3.019 3.837 3.752 3.002 3.118
    Accrued Expenses 8.047 6.856 4.303 7.235 5.478
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 0.77 3.117 3.431 0.456 0.917
    Total Liabilities 18.036 17.683 15.061 13.524 11.946
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 6.2 3.873 3.575 2.831 2.433
    Total Equity 62.978 68.647 77.561 84.74 87.986
    Common Stock 0.003 0.003 0.003 0.003 0.003
    Additional Paid-In Capital 347.192 343.769 342.4 339.825 337.995
    Retained Earnings (Accumulated Deficit) -290.904 -282.192 -271.808 -262.588 -257.235
    Other Equity, Total 6.687 7.067 6.966 7.5 7.223
    Total Liabilities & Shareholders’ Equity 81.014 86.33 92.622 98.264 99.932
    Total Common Shares Outstanding 25.5507 25.4476 25.3278 25.2084 25.0309
    Cash & Equivalents 50.854 37.485 28.05 18.164 23.613
    Short Term Investments 9.264 28.562 45.401 61.178 60.559
    Long Term Investments 0 2.754 4.189 6.93 4.012
    • Annual
    • Quarterly
    2022 2021 2021 2020
    Net income/Starting Line -26.665 -14.427 -26.583 -42.03
    Cash From Operating Activities -19.09 -5.501 -25.901 -22.747
    Cash From Operating Activities 0.568 0.33 0.715 0.465
    Non-Cash Items 8.203 3.921 7.323 17.488
    Cash Interest Paid 0.015 0.017 0.003 0.042
    Changes in Working Capital -1.196 4.675 -7.356 1.33
    Cash From Investing Activities -19.332 -49.682 -1.174 -0.847
    Capital Expenditures -0.452 -0.132 -1.174 -0.847
    Cash From Financing Activities 0.9 0.007 64.049 77.057
    Financing Cash Flow Items 0 -5.109 -5.077
    Issuance (Retirement) of Stock, Net 0.9 0.007 69.169 82.176
    Issuance (Retirement) of Debt, Net 0 0 -0.011 -0.042
    Foreign Exchange Effects -0.026 -0.059 0.133 0.003
    Net Change in Cash -37.548 -55.235 37.107 53.466
    Cash Taxes Paid 0.017 0.008 0.042
    Other Investing Cash Flow Items, Total -18.88 -49.55
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -9.22 -26.665 -21.312 -15.724 -9.463
    Cash From Operating Activities -9.073 -19.09 -15.654 -12.877 -9.37
    Cash From Operating Activities 0.135 0.568 0.438 0.3 0.163
    Non-Cash Items 3.347 8.203 6.697 5.004 3.383
    Cash Taxes Paid 0.009 0.017 0.017 0.017
    Cash Interest Paid 0.004 0.015 0.01 0.004 0
    Changes in Working Capital -3.335 -1.196 -1.477 -2.457 -3.453
    Cash From Investing Activities 18.787 -19.332 -16.174 -7.845 -22.601
    Capital Expenditures -0.284 -0.452 -0.382 -0.278 -0.064
    Cash From Financing Activities 0.171 0.9 0.001 0.001 0.001
    Financing Cash Flow Items 0 0
    Issuance (Retirement) of Stock, Net 0.171 0.9 0.001 0.001 0.001
    Issuance (Retirement) of Debt, Net 0 0
    Foreign Exchange Effects 0.001 -0.026 -0.07 -0.052 -0.006
    Net Change in Cash 9.886 -37.548 -31.897 -20.773 -31.976
    Other Investing Cash Flow Items, Total 19.071 -18.88 -15.792 -7.567 -22.537

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    AVITA Medical, Inc. Company profile

    About AVITA Medical Inc

    AVITA Medical, Inc. is a regenerative medicine company. The Company is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. It provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, AVITA Medical Inc revenues totaled $14M. Net loss totaled to $14.4M. Results are not comparable due to year end change.

    Industry: Biotechnology & Medical Research (NEC)

    28159 Avenue Stanford
    Suite 220
    VALENCIA
    CALIFORNIA 91355
    US

    Income Statement

    • Annual
    • Quarterly

    News

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    Higher CPI leaves traders unfazed as US equities continue to build momentum

    The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

    12:42, 15 March 2024

    People also watch

    ETH/USD

    3,064.43 Price
    -0.420% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    62,920.30 Price
    -0.210% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    Gold

    2,390.81 Price
    +0.460% 1D Chg, %
    Long position overnight fee -0.0191%
    Short position overnight fee 0.0108%
    Overnight fee time 21:00 (UTC)
    Spread 0.40

    US100

    17,748.90 Price
    +0.370% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading